Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Galderma Group AGGDERF -4.36%21 5-Year Yield-on-Cost % is 0.22 as of Jul. 15, 2026, which is 144% above its 10-year median of 0.09. GuruFocus rates GDERF with a GF Score™ of 21/100. The stock has 4 warning signs investors should review. Among 515 Drug Manufacturers companies, Galderma Group AG ranks worse than 93.4% on this metric.
Galderma Group AG's yield on cost for the quarter that ended in Dec. 2025 was 0.22.
The historical rank and industry rank for Galderma Group AG's 5-Year Yield-on-Cost % or its related term are showing as below:
GDERF'
s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 0.08 Med: 0.09 Max: 0.22
Current: 0.22
During the past 5 years, Galderma Group AG's highest Yield on Cost was 0.22. The lowest was 0.08. And the median was 0.09.
GDERF's 5-Year Yield-on-Cost % is ranked worse than 93.4% of 515
companies
in the Drug Manufacturers industry
Industry Median: 2.25
vs GDERF: 0.22
Galderma Group AG (OTCPK:GDERF) 5-Year Yield-on-Cost % Explanation
Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.
Galderma Group AG 5-Year Yield-on-Cost % Related Terms
GDERF vs ZTS, UTHR, VTRS: 5-Year Yield-on-Cost % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Galderma Group AG's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Galderma Group AG 5-Year Yield-on-Cost % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Galderma Group AG's 5-Year Yield-on-Cost % distribution charts can be found below:
* The bar in red indicates where Galderma Group AG's 5-Year Yield-on-Cost % falls into.
Galderma Group AG 5-Year Yield-on-Cost % Calculation
Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.
Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.
Galderma Group AG (GDERF) has a 5-Year Yield-on-Cost % of 0.22 as of Jul. 15, 2026. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Galderma Group AG and its competitors. This is 144% above median its historical median of 0.09. Over the past decade, Galderma Group AG's 5-Year Yield-on-Cost % has ranged from 0.08 to 0.22. According to the industry distribution chart, Galderma Group AG ranks #481 out of 515 companies in the Drug Manufacturers industry, placing it in the top 93.4%.
Is Galderma Group AG's 5-Year Yield-on-Cost % too high?
Galderma Group AG's current 5-Year Yield-on-Cost % of 0.22 is 144% above median its 10-year median of 0.09. Over the past 10 years, this metric has ranged from a low of 0.08 to a high of 0.22. The Drug Manufacturers industry median 5-Year Yield-on-Cost % is 2.25. Galderma Group AG's value of 0.22 is 90.2% below this industry median. Based on the distribution chart, Galderma Group AG ranks #481 out of 515 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Galderma Group AG has a GF Score™ of 21/100, reflecting its overall financial health beyond just this single metric.
How does Galderma Group AG's 5-Year Yield-on-Cost % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Galderma Group AG ranks #481 out of 515 companies for 5-Year Yield-on-Cost %. This places Galderma Group AG in the lower half of its industry. The industry median 5-Year Yield-on-Cost % is 2.25. Galderma Group AG's value of 0.22 is 90.2% below this benchmark. Historically, Galderma Group AG's own 5-Year Yield-on-Cost % has ranged from 0.08 to 0.22 over the past decade. While the company's 10-year median is 0.09 vs. the industry median of 2.25, Galderma Group AG has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year Yield-on-Cost % for a Drug Manufacturers company?
The median 5-Year Yield-on-Cost % among Drug Manufacturers companies is 2.25, based on 515 companies in the industry. Companies in the top quartile (top 25%) have a 5-Year Yield-on-Cost % significantly above this median, while those in the bottom quartile fall well below. However, 5-Year Yield-on-Cost % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Galderma Group AG's current 5-Year Yield-on-Cost % of 0.22 is 90.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year Yield-on-Cost % mean?
A high 5-Year Yield-on-Cost % can signal that a stock is expensive relative to its fundamentals. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Galderma Group AG and its competitors. For the Drug Manufacturers industry, the median 5-Year Yield-on-Cost % is 2.25 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Galderma Group AG's current 5-Year Yield-on-Cost % is 0.22, which is 144% above median its own 10-year median of 0.09. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Galderma Group AG stock overvalued right now?
Galderma Group AG (GDERF) has a current 5-Year Yield-on-Cost % of 0.22. The current 5-Year Yield-on-Cost % is 0.22, which is 144% above median its 10-year median of 0.09 and 90.2% below the Drug Manufacturers industry median of 2.25. Galderma Group AG's overall GF Score™ is 21/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year Yield-on-Cost % calculated?
5-Year Yield-on-Cost % is calculated from a company's financial statements. For Galderma Group AG (GDERF), the current 5-Year Yield-on-Cost % is 0.22 as of Jul. 15, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Galderma was formed in 1981 as a joint venture between Nestle and L'Oreal. It subsequently became a subsidiary of Nestle, called Nestle Skin Health, before being carved out and launched as a stand-alone company in 2019, acquired by a consortium led by Sweden-based EQT fund. The company went public in March 2024 and is listed on the SIX Swiss exchange. Galderma's science-based portfolio spans multiple dermatology categories, including injectable aesthetics, dermatological skincare, and therapeutic dermatology. It derives around 40% of net sales from the US and employs more than 7,500 people.
21GF Score
Get the complete analysis for GDERF
5-Year Yield-on-Cost % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
GDERF has been successfully added to your 
